Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 18/20 | 0.56 |
| ▸ | HTR2A | P28223 | 13/20 | 0.56 |
| ▸ | HTR2B | P41595 | 12/20 | 0.56 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6681416 | 1.00 | MTNR1B (0.59) | MTNR1BHTR2CHTR2AHTR2BSLC9A1 | |
| SCHEMBL30529740 | 1.00 | MTNR1B (0.59) | MTNR1BHTR2CHTR2AHTR2BSLC9A1 | |
| SCHEMBL28417583 | 1.00 | MTNR1B (0.59) | MTNR1BHTR2CHTR2AHTR2BSLC9A1 | |
| SCHEMBL27887835 | 1.00 | MTNR1B (0.59) | MTNR1BHTR2CHTR2AHTR2BSLC9A1 | |
| SCHEMBL17269309 | 1.00 | MTNR1B (0.59) | MTNR1BHTR2CHTR2AHTR2BSLC9A1 | |
| SCHEMBL15255143 | 1.00 | MTNR1B (0.59) | MTNR1BHTR2CHTR2AHTR2BSLC9A1 | |
| SCHEMBL6682129 | 1.00 | MTNR1B (0.59) | MTNR1BHTR2CHTR2AHTR2BSLC9A1 | |
| Hydrochloric Acid SCHEMBL19063473 | 0.98 | HTR2C (0.59) | MTNR1BHTR2CHTR2AHTR2BSLC9A1 | |
| SCHEMBL6679818 | 0.90 | MTNR1B (0.49) | MTNR1BHTR2CHTR2AHTR2BSLC9A1 | |
| SCHEMBL6679811 | 0.90 | MTNR1B (0.49) | MTNR1BHTR2CHTR2AHTR2BSLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382883-A1 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | VANDA PHARMACEUTICALS INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382883-A1 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | VANDA PHARMACEUTICALS INC. | 2023-11-30 | — | — | US | disclosed |
| US-11760740-B2 | Highly purified pharmaceutical grade tasimelteon | VANDA PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| EP-4223747-A1 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | Vanda Pharmaceuticals Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| US-11566011-B2 | Highly purified pharmaceutical grade tasimelteon | VANDA PHARMACEUTICALS INC. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-3470405-A1 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | Vanda Pharmaceuticals Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| US-9944616-B2 | Processes for the preparation of Tasimelteon and intermediates thereof | APOTEX INC. (CA) | 2018-04-17 | — | — | US | disclosed |
| US-9944616-B2 | Processes for the preparation of Tasimelteon and intermediates thereof | APOTEX INC. (CA) | 2018-04-17 | — | — | US | disclosed |
| US-20170355688-A1 | Processes for the Preparation of Tasimelteon and Intermediates Thereof | THE BANK OF NOVA SCOTIA (CA) | 2017-12-14 | — | — | US | disclosed |
| US-20170355688-A1 | Processes for the Preparation of Tasimelteon and Intermediates Thereof | THE BANK OF NOVA SCOTIA (CA) | 2017-12-14 | — | — | US | disclosed |
| US-20170190683-A1 | HIGHLY PURIFID PHARMACEUTICAL GRADE TASIMELTEON | VANDA PHARMACEUTICALS INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170190683-A1 | HIGHLY PURIFID PHARMACEUTICAL GRADE TASIMELTEON | VANDA PHARMACEUTICALS INC. | 2017-07-06 | — | — | US | disclosed |
| WO-2015123389-A1 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | VANDA PHARMACEUTICALS INC. (US) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566011-B2 | Highly purified pharmaceutical grade tasimelteon | GMPS, TAS2R45, TAS2R10 | MTNR1B 2331/4885HTR2C 1757/4885HTR2A 581/4885 |
| US-20170190683-A1 | HIGHLY PURIFID PHARMACEUTICAL GRADE TASIMELTEON | GMPS, TAS2R60, TAS2R20 | MTNR1B 3291/4885HTR2C 852/4885HTR2A 316/4885 |
| US-20230382883-A1 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | GMPS, TAS2R45, TAS2R10 | MTNR1B 2331/4885HTR2C 1757/4885HTR2A 581/4885 |
| US-11760740-B2 | Highly purified pharmaceutical grade tasimelteon | GMPS, TAS2R45, TAS2R10 | MTNR1B 2331/4885HTR2C 1757/4885HTR2A 581/4885 |
| US-20170355688-A1 | Processes for the Preparation of Tasimelteon and Intermediates Thereof | TRMT1, SULT1A1, TMT1A | MTNR1B 1442/4885HTR2C 2546/4885HTR2A 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.